The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients
Open accessAbstract
Significant anti-tumor responses have been reported in a small subset of cancer patients treated with the immunotherapeutic agent anti-CTLA-4 antibody. All clinical trials to date, comprising over 3,000 patients, have been conducted in the metastatic disease setting, which allows for correlation of drug administration with clinical outcome but has limited analyses of intermediate biomarkers to indicate whether the drug has impacted human immune responses within the tumor microenvironment. We conducted a pre-surgical clinical trial in six patients with localized bladder cancer, which allowed for correlation of drug administration with biomarkers in both blood and tumor tissues but did not permit correlation with clinical outcome. We found that CD4 T cells from peripheral blood and tumor tissues of all treated patients had markedly increased expression of inducible costimulator (ICOS). These CD4(+)ICOS(hi) T cells produced IFN-gamma (IFNgamma) and could recognize the tumor antigen NY-ESO-1. Increase in CD4(+)ICOS(hi) cells led to an increase in the ratio of effector to regulatory T cells. To our knowledge, these are the first immunologic changes reported in both tumor tissues and peripheral blood as a result of treatment with anti-CTLA-4 antibody, and they may be used to guide dosing and scheduling of this agent to improve clinical responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the immune monitoring studies performed on the trial highlighted the reverse translational approach and identified ICOS + CD4 T cells as a novel subset of T cells associated with anti-CTLA4 therapy (17,18,171,172).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The increased abundance of ICOS + CD4 + T cells resulted in an increased ratio of these cells to Tregs (156) both in the tumor and in peripheral blood.”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [156]
In the citing paper
“Anti-CTLA4 predominantly affects CD4 T cells, with multiple studies identifying increased frequency of a Th1 subset of CD4 T cells that express inducible costimulator (ICOS) as a result of anti-CTLA4 therapy (17)(18)(19).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [18]
In the citing paper
“Immune co-stimulator (ICOS) is a co-stimulatory molecule expressed on T cells, which enhances function and expansion of CD8+ T cells and Tregs (Fu et al., 2011; Hutloff et al., 1999; Liakou et al., 2008).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Liakou et al., 2008
In the citing paper
“in patients with bladder cancer, CTLA-4 blockade led to increased inducible T cell costimulator (ICOS) expression on IFN-γ producing CD4 + T cells.”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Zheng, W.-P., & Flavell, R. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80240-8 · Cited by 2,384
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“CD28-mediated T cell expansion is opposed by another B7–1,2 counter receptor, cytotoxic T lymphocyteassociated antigen 4 (CTLA-4), which attenuates the proliferation of recently activated T cells (4, 5).”
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,559
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
“To date, no such pretreatment biomarker has been validated to the point at which it could be applied as part of standard-of-care therapeutic decision-making, although insights have emerged from the identification of certain post-treatment immune responses that seem to correlate with clinical outcom”
BackgroundThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
“ICOS + effector T cells (Teff), as opposed to ICOS + regulatory T cells (Treg), increase after patients receive treatment with anti-CTLA-4 (Liakou et al., 2008), correlating with clinical benefit in a small retrospective study (Carthon et al., 2010).”
Background
Metadata
- Authors
- Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-09-30
- Volume
- 105
- Issue
- 39
- Pages
- 14987-14992
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2567480
- OpenAlex
- W1981528932
- Cited by
- 549
- References
- 32
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 36 · 2023: 20 · 2022: 28 · 2021: 44 · 2020: 41 · 2019: 44 · 2018: 44 · 2017: 37 · 2016: 47 · 2015: 39 · 2014: 23 · 2013: 32 · 2012: 20
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, anti-CTLA-4 antibody, ICOS, CD4+ T cells, interferon-gamma, regulatory T cells, bladder cancer, NY-ESO-1, tumor microenvironment, cancer immunotherapy, biomarkers, localized bladder cancer
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antigens, Differentiation, T-Lymphocyte, Urinary Bladder Neoplasms, Carcinoma, Humans, Interferon-gamma, Antigens, CD, CD4 Antigens, T-Lymphocytes, Regulatory, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients. https://app.cochat.ai/papers/10.1073/pnas.0806075105
- The paper
- Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008). CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0806075105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.